
|Videos|May 26, 2017
Dr. Strosberg on Understanding the Current Field of Neuroendocrine Tumors
Author(s)Jonathan R. Strosberg, MD
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
Advertisement
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, shares his insight on the current field of neuroendocrine tumors (NETs).
After years of everolimus (Afinitor) and metastin analogs, the field is in a stage of expansion, says Strosberg. Agents such as telotristat ethyl (Xermelo) are signifying that new drugs—although niche—are signaling advancement in the treatment of NETs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































